Myelofibrosis
📧 Sign up to get email alerts when something new happens for Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
This document reports an update on a clinical trial comparing stem cell transplantation with non-transplant therapies for patients with high…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
This entry describes the MPN PROGRESSion Registry, an observational study to track symptoms, treatments, and disease progression in people w…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey
A completed Turkish study analyzes demographics and treatment patterns of myelofibrosis patients treated with ruxolitinib.
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors [Phase 1, Phase 2]
Clinical trial update on Roginolisib in combination with Ruxolitinib for myelofibrosis patients unresponsive to JAK inhibitors. The study is…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels
This document is a clinical trial update describing a long-term study of Gecacitinib for myelofibrosis, including assessment of its effects …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-13EMA Authorised: Inrebic (fedratinib dihydrochloride monohydrate) — Bristol Myers Squibb Pharma EEIG
The European Medicines Agency authorised Inrebic for myeloproliferative neoplasms, including primary myelofibrosis, with Bristol Myers Squib…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating elotuzumab for JAK2-mutated myelofibrosis; the study is active but not recruiting and includes myelofibros…
-
CLINICAL_TRIALS trial_result · 2026-01-12Clinical Trial Update: Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating reduced intensity haploidentical transplantation for primary or secondary myelofibrosis is currently recru…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors [Phase 1, Phase 2]
A first-in-human Phase 1/2 trial of JAB-8263 in adults with advanced tumors is currently recruiting across multiple cancer types including l…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis [Phase 3]
Phase 3 trial update evaluating navitoclax plus ruxolitinib versus best available therapy to assess spleen volume changes in adults with rel…
-
CLINICAL_TRIALS other · 2026-01-07Clinical Trial Update: Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) [Phase 2]
This is a Phase 2 clinical trial evaluating reparixin in patients with myelofibrosis and related myeloproliferative neoplasms; the study is …
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis
The study investigates the role of myeloid-derived suppressor cells in primary myelofibrosis, and the trial has completed.
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis [Phase 1]
Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of imetelstat in combination with ruxolitinib…
-
CLINICAL_TRIALS trial_result · 2026-01-05Clinical Trial Update: A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT [Phase 1]
Phase 1 trial evaluating a combination of CD25/Treg-depleted donor lymphocyte infusion with ipilimumab for relapse of myeloid diseases after…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) [Phase 1, Phase 2]
This Phase I/II clinical trial is evaluating Axatilimab, a CSF1R monoclonal antibody, in combination with ruxolitinib for myelofibrosis and …
-
CLINICAL_TRIALS withdrawal · 2026-01-05Clinical Trial Update: A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating TQ05105 in combination with TQB3909 for myelofibrosis was terminated. No results are provided in…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Selumetinib and Azacitidine in High Risk Chronic Blood Cancers [Phase 1]
A Phase 1 clinical trial evaluating the combination of selumetinib and azacitidine in high-risk chronic myeloid leukemia and myelofibrosis i…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
This clinical trial update describes a study on clinical epidemiology in contemporary patients with myelofibrosis and is currently recruitin…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders [Phase 1, Phase 2]
Clinical trial update shows INCB000928 is being studied as a monotherapy or in combination with ruxolitinib for anemia due to myeloprolifera…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis [Phase 2]
Phase 2 study of TQ05105 tablets for moderate-to-high-risk myelofibrosis is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial [Phase 2]
A Phase 2 clinical trial called TREATMORE evaluating MethoTRExATE in myeloproliferative neoplasms is currently recruiting for polycythemia v…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets [Phase 1]
The Phase 1 study evaluating drug-drug interactions of TQ05105 tablets has completed.
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib [Phase 2]
This clinical trial update describes a Phase 2 rollover study of Itacitinib to provide continued treatment for participants previously enrol…
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes [NA]
A clinical trial is ongoing to characterize monocytes in myeloproliferative neoplasms, with recruitment currently in progress.
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study of the combination of TQ05105 tablets and TQB3617 capsules in patients with myelofibros…